Tsunemoto H, Morita S, Satoh S, Iino Y, Yoo Y
National Institute of Radiological Sciences, Chibashi, Japan.
Strahlenther Onkol. 1989 Apr;165(4):330-6.
The present status of the treatment with fast neutrons performed in Asian countries is reviewed and the experiences with respect to the radiobiological indications are presentated and discussed. There are three facilities under operation, the National Institute of Radiological Sciences (NIRS) in Chiba, the Institute of Medical Science (IMS) in Tokyo and the Korea Cancer Center Hospital (KCCH) in Seoul. The clinical experiences can be summarized as follows: Fast neutrons are the treatment of choice for carcinoma of the salivary gland, Pancoast tumor of the lung, osteosarcoma, soft tissue sarcoma and malignant melanoma. Provided the isodose planning can be improved, it seems that also squamous cell carcinoma of the head and neck and esophagus, adenocarcinoma of the lung, stage I and prostatic adenocarcinoma can be benefit from neutron therapy. The same holds for malignant meningioma, while the benefit for glioblastoma multiforme has not yet been confirmed. Studies are going on for the treatment of other cancers and for evaluating the possible role of neutron therapy in combination with surgery.
本文综述了亚洲国家开展快中子治疗的现状，并介绍和讨论了放射生物学适应症方面的经验。目前有三个机构在运行，分别是千叶的国立放射科学研究所（NIRS）、东京的医学科学研究所（IMS）和首尔的韩国癌症中心医院（KCCH）。临床经验可总结如下：快中子是唾液腺癌、肺上沟瘤、骨肉瘤、软组织肉瘤和恶性黑色素瘤的首选治疗方法。如果能改进等剂量计划，头颈和食管鳞状细胞癌、肺腺癌、I期前列腺腺癌似乎也可从中子治疗中获益。恶性脑膜瘤也是如此，而多形性胶质母细胞瘤的获益尚未得到证实。针对其他癌症的治疗以及评估中子治疗联合手术的可能作用的研究正在进行。
